Cash injection

GlaxoSmithKline (GSK) is planning to invest zł.88 million and create 69 new jobs in Poznań this year.

The pharmaceutical giant is launching production of four new drugs (Pylorid, Imigran, Naramig and Lamictal) in its Poznań plant, and the facility will also supply the world market with all of GSK's antiretroviral drugs, which are used in the treatment of HIV and AIDS.

Last year the company invested zł.34 million in distribution and storage facilities and a regional IT support center. "Investments implemented in 2005 and planned for 2006 confirm that the Polish branch of GSK plays a very important role in the company's global structure. This also verifies our long-term strategy, which we have been consistently realizing on the Polish market," said Cameron Marshall, president of GSK Pharmaceuticals.

The Polish plant is set to ramp up drug production by 21 million packets, meaning total output of 106 million packets a year.

"We have a very modern production facility, so we are not afraid of new challenges. Our products are in line with the most rigorous quality standards. Our drugs will be used not only in Poland, but nearly in the entire world," said Izabela Wachowiak, director of the GSK branch in Poznań.